Tradestie Institutional Equity Comparison Engine

VSTM vs DMAC โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DMAC Overall Edge

DMAC Captures Institutional Edge (3โ€“0 Pillars ยท 3โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, VSTM trades at N/M Forward P/E with -193.7% operating margin (+113.6% YoY revenue) versus DMAC at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, VSTM sits in CONSOLIDATION (10th %ile IV; Dealer Gamma Walls on Pro) against DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
VSTM N/M vs DMAC N/M Fwd P/E
Growth & Margin Winner DMAC
Op Margin -193.7% vs 0.0% ยท YoY +113.6% vs +0.0%
Momentum & Technical Winner DMAC
1Y -2.8% vs +55.3% ยท 52W Pos 60% vs 55%
Options & Structure Winner DMAC
CONSOLIDATION (10th %ile IV) vs SURGE (14th %ile IV)
VSTM NASDAQ
Verastem, Inc.
Pharmaceutical Preparations
$7.88
-3.67% 1D
Market Cap $1.1B
1M Return -8.9%
1Y Return -2.84%
Forward P/E N/M
Unified AI Score
56.9 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 64.0 Mom 70.0
DMAC NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
1M Return +11.16%
1Y Return +55.26%
Forward P/E N/M
Unified AI Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: VSTM -2.84% DMAC +55.26% Spread: +58.1 pp (DMAC Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period VSTM Revenue DMAC Revenue VSTM Op. Margin DMAC Op. Margin Margin Edge
FY2018 $30M $0M -354.8% -1352.2% VSTM
FY2019 $20M N/A -758.1% N/A VSTM
FY2020 $90M N/A -55.8% N/A VSTM
FY2021 $0M N/A -2991.2% N/A VSTM
FY2022 $0M N/A -2809.6% N/A VSTM
FY2024 $10M N/A -1149.6% N/A VSTM
FY2025 $30M N/A -550.3% N/A VSTM

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: VSTM (5) vs DMAC (3)
Institutional Metric VSTM DMAC Criterion Row Winner
Market Capitalization Scale $1.1B $503.1M Larger Scale VSTM
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +113.6% +0.0% Higher Growth VSTM
Operating Margin (TTM) Profitability -193.7% 0.0% Higher Margin DMAC
Net Profit Margin Profitability -178.4% 0.0% Higher Margin DMAC
Return on Equity (ROE) Capital Efficiency -471.2% -114.6% Higher ROE DMAC
52-Week Range Position Momentum 60% ($3โ€“$11) 55% ($5โ€“$11) Stronger Trend VSTM
Beta / 30D Volatility Risk Regime 1.11ฮฒ ยท 71% Vol 1.74ฮฒ ยท 98% Vol Lower Realized Risk VSTM
Unified Institutional Score Composite Signal 56.9 / 100 (HOLD) 46.3 / 100 (HOLD) Higher Composite VSTM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full VSTM vs DMAC Buy Guide
VSTM CONSOLIDATION
50d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live VSTM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DMAC SURGE
8d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 14th %ile
IV Regime Compressed (<25th %ile)
Live DMAC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither VSTM nor DMAC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.